|
News GSK and Theravance announce initial outcomes from pivotal Phase III studies for once-daily Relovair in COPD and asthma
GlaxoSmithKline and Theravance, Inc. announced the completion of the phase III registration programme for the once-daily investigational medicine Relovair |
|
Article Theravance
Our objective is to discover, develop and commercialize new medicines with superior efficacy, convenience, tolerability and/or safety. |